The strategic addition of immune checkpoint inhibitors (ICIs) to chemotherapy (CT) offers a potential paradigm shift in the treatment of elderly cancer patients.
This systematic review evaluates the impact of ICIs combined with CT on the overall survival (OS) of patients aged 65 and older.
